Trial Profile
A phase 1 study of 5-FU and sorafenib combination therapy in patients with hepatocellular carcinoma. Non-blind dosage gradual increase study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jul 2020
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Biomarker
- 17 Jul 2020 Added first line therapy to patient segments because exclusion criteria states: "Any systemic chemotherapy in past."
- 13 Jul 2020 Status changed from active, no longer recruiting to completed.
- 01 Jun 2017 Results published in the Drugs in R and D